{"id":"delamanid-dlm","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Delamanid is a prodrug that is activated by mycobacterial enzymes to form reactive intermediates that inhibit the DprE1 enzyme, which is essential for the synthesis of mycolic acids—critical components of the mycobacterial cell wall. By disrupting cell wall integrity, delamanid leads to bacterial death and is particularly effective against drug-resistant tuberculosis strains.","oneSentence":"Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:58.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Drug-resistant tuberculosis (MDR-TB and XDR-TB)"},{"name":"Pulmonary tuberculosis in combination with other anti-TB agents"}]},"trialDetails":[{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT05007821","phase":"PHASE2","title":"Linezolid Dosing Strategies in Drug-Resistant TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-11","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary","enrollment":138},{"nctId":"NCT03568383","phase":"PHASE3","title":"Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-03","conditions":"Tuberculosis, MDR","enrollment":5832},{"nctId":"NCT03141060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-30","conditions":"Tuberculosis, HIV Infections","enrollment":37},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT06476210","phase":"PHASE4","title":"The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2024-06","conditions":"Pulmonary Tuberculosis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Delamanid (DLM)","genericName":"Delamanid (DLM)","companyName":"Wuhan Pulmonary Hospital","companyId":"wuhan-pulmonary-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-TB agents.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}